Redox-modulating agents target NOX2-dependent IKKε oncogenic kinase expression and proliferation in human breast

Espérance Mukawera1, Stefany Chartier1, Virginie Williams2

  • 1CRCHUM - Centre Hospitalier de l'Université de Montréal, 900 Rue Saint Denis, Montréal, QC, Canada H2X 0A9.

Redox Biology
|July 16, 2015
PubMed

Insights

Redox-modulating compounds like Gentian Violet, Brilliant Green, and Tempol reduce oxidative stress and inhibit IKKε expression in breast cancer cells. These findings suggest potential new therapies targeting NOX2 for breast carcinomas with IKKε amplification.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Oxidative stress contributes to cancer development and chemotherapy resistance.
  • Increased IKKε kinase levels are linked to breast carcinomas and tamoxifen resistance.
  • Understanding redox modulator effects on molecular pathways is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the impact of redox-modulating compounds on IKKε expression and proliferation in breast cancer cells.
  • To explore the role of superoxide anion and NOX2 in IKKε-driven breast cancer.

Main Methods:

  • In vitro treatment of MCF-7 and ZR75.1 breast cancer cell lines with Gentian Violet, Brilliant Green, and Tempol.
  • Measurement of intracellular superoxide anion levels, IKKε expression, and cell viability.
  • Analysis of cyclin D1 and caspase 3/7 activation.
  • Silencing of NOX2 NADPH oxidase.

Main Results:

  • Gentian Violet, Brilliant Green, and Tempol decreased superoxide anion levels, inhibited IKKε expression, and reduced cell viability.
  • These compounds also affected cyclin D1 expression and caspase activation.
  • Silencing NOX2 significantly reduced IKKε expression, highlighting its role.

Conclusions:

  • Redox modulators targeting NOX2 show promise for treating breast carcinomas with IKKε amplification.
  • These compounds may offer therapeutic benefits in combination therapies.
  • Further research into NOX2-targeted strategies is warranted.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.0K